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Comparison of lipases for in vitro models of
gastric digestion: lipolysis using two infant
formulas as model substrates
P. J. Sassene,a M. Fanø,b H. Mu,a T. Rades,a S. Aquistapace,c B. Schmitt,c
C. Cruz-Hernandez,c T. J. Woosterc and A. Müllertz*a,b
The aim of this study was to ﬁnd a lipase suitable as a surrogate for Human Gastric Lipase (HGL), since the
development of predictive gastrointestinal lipolysis models are hampered by the lack of a lipase with
similar digestive properties as HGL. Three potential surrogates for HGL; Rhizopus Oryzae Lipase (ROL),
Rabbit Gastric Lipase (RGL) and recombinant HGL (rHGL), were used to catalyze the in vitro digestion of
two infant formulas (a medium-chain triacylglyceride enriched formula (MC-IF) and a predominantly
long-chain triacylglyceride formula (LC-IF)). Digesta were withdrawn after 0, 5, 15, 30, 60 min of gastric
digestion and after 90 or 180 min of intestinal digestion with or without the presence of pancreatic
enzymes, respectively. The digesta were analyzed by scanning electron microscopy and gas chromato-
graphy to quantify the release of fatty acids (FAs). Digestions of both formulas, catalyzed by ROL, showed
that the extent of gastric digestion was higher than expected from previously published in vivo data. ROL
was furthermore insensitive to FA chain length and all FAs were released at the same pace. RGL and rHGL
favoured the release of MC-FAs in both formulas, but rHGL did also release some LC-FAs during digestion
of MC-IF, whereas RGL only released MC-FAs. Digestion of a MC-IF by HGL in vivo showed that MC-FAs
are preferentially released, but some LC-FAs are also released. Thus of the tested lipase rHGL replicated
the digestive properties of HGL the best and is a suitable surrogate for HGL for use in in vitro gastrointestinal
lipolysis models.
Introduction
In humans, the digestion of lipids is initiated in the stomach
and is catalyzed by human gastric lipase (HGL).1–3 HGL is
secreted by the chief cells in the fundus and corpus regions of
the stomach along with pepsin and is the only pre-duodenal
lipase in humans.1,4–6 HGL is catalyzing approximately
10–45% of the total triacylglyceride (TAG) hydrolysis through-
out the gastrointestinal (GI)-tract in healthy adults and even
more for people experiencing insuﬃcient secretion of exocrine
enzymes from the pancreas, such as infants or patients
suﬀering from pancreatitis or cystic fibrosis.2,7–11 In infants
gastric lipase hydrolyses 10–30% of TAGs, however, gastric
lipase is also thought to play a critical role in enabling pan-
creatic lipases to catalyse lipid digestion in infants feed breast
milk.12–15 Bernback et al. found that pancreatic lipase is not
able to digest TAGs of native human milk without catalytic
pre-digestion by gastric lipase which helps to distrupt their
native milk fat globule membrane.12,13 Given the important
role that gastric lipase plays in infants and adults with pan-
creatic insuﬃciency it is important to have in vitro models that
accurately replicate its action.
Several diﬀerent digestion models have been developed to
simulate lipid digestion occurring throughout the gastrointes-
tinal (GI)-tract in order to evaluate nutritional and pharma-
ceutical products. The majority of these in vitro lipolysis
models are only taking the intestinal digestion into
account.16–28 This is due to several reasons of which the most
crucial one is that the majority of lipid digestion occurs in the
proximal part of the small intestine. The throughput of the
models is another important parameter, as shorter digestion
times are needed when only intestinal digestion is performed.
The intestine is furthermore the primary site of absorption for
macronutrients, micronutrients and active pharmaceutical
ingredients (API), thus making it inherently important, as the
aqueous solubility in intestinal fluid of APIs has been shown
to correlate with the in vivo bioavailability.29,30 The incorpo-
ration of a gastric compartment to the intestinal in vitro lipoly-
sis models has, however, also been hampered by the lack of
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availability of lipases with similar digestive properties as HGL.
HGL is an acid stable lipase active in the pH-range 2–8 with
pH-optima between 4–6 depending on the substrate.31–33 Its
activity throughout a broad pH-range makes it unique com-
pared to pancreatic lipases, only displaying activity above pH
4.5.2,34 HGL does furthermore display a higher specific activity
towards short chain (SC)- and medium chain (MC)-TAGs than
long chain (LC)-TAGs.32,35 The catalytic aﬃnity of HGL is
solely towards FAs situated at the terminal carbons on the gly-
cerol backbone, and primarily the sn-3 position.35 Sampling
HGL from humans is diﬃcult for ethical reasons and its
natural low abundance compared to the pancreatic enzymes.1,2
Thus alternative lipases have been explored as substitutes for
HGL in in vitro models.
A number of microbial lipases such as Rhizopus oryzae
lipase (ROL) and Candida antarctica lipase A (CALA) have been
used to mimic gastric digestion in vitro.27,36,37 ROL is facilitat-
ing digestion at the sn-1 and sn-3 position (as does HGL), but
HGL has a preference towards the sn-3 position whereas ROL
shows a higher aﬃnity towards the sn-1 position.35,36,38 ROL is
commonly used in more complex in vitro digestion models,
such as the TNO gastrointestinal model (TIM) and the
Dynamic Gastric Model (DGM).27,39–42 The digestion products
resulting from a complex dietary product, e.g. an infant
formula, following digestion catalyzed by ROL have, to the best
of the authors knowledge, never been compared with the
digestion catalyzed by HGL. Thus ROL’s utility as a substitute
for HGL in in vitro digestion models is still to be validated.
CALA has also been used for in vitro gastric digestion, since it
has been shown to have a comparable activity-pH profile as
rabbit gastric lipase (RGL), as well as a similar pH-optimum.37
The digestion catalyzed by CALA has, however, previously been
shown to occur predominantly on the sn-2 position, which
HGL has no aﬃnity for.35,38 This is particularly problematic,
if the digestion model is simulating both gastric and
intestinal compartments, since pancreatic lipase is sn-1 and
sn-3 specific.35 Thus an overestimation of TAG liberated of all
three fatty acids (FA) might occur, which would not take place
in vivo where 2-monoglycerides are readily absorbed.21,43,44
Animal derived lipases, such as dog gastric lipase (DGL) and
RGL have also been used for in vitro gastric digestion.45–48
DGL shows a higher activity towards LC-TAG than SC-TAG.45
This is a problem when digesting complex meals or drug deliv-
ery systems containing TAGs with FAs of varying chain lengths
and DGL is therefore not suitable as a surrogate for HGL.
Diﬀerent studies with RGL have demonstrated, that RGL
seems like a sensible replacement for HGL, as the rate of
digestion has been shown to be comparable when using these
two lipases.47 RGL does, however, have a lower specific activity
than HGL.45,47 Studies comparing digestion products after
lipolysis catalyzed by RGL and HGL have investigated the for-
mation of monoacylglycerides (MAG) and diacylglycerides
(DAG) from a solid meal.47 However, the relative preference of
RGL for hydrolysis of FAs with diﬀerent chain lengths has not
been compared with HGL and might indeed play a crucial role
in replicating nutrient update (in the infant for example), but
also for solubilization of poorly water soluble micronutrients
or APIs.49,50
The shortcomings of the above mentioned animal and
microbial lipases, with regard to digestive properties compared
to HGL, have lead to the expression of recombinant human
gastric lipase (rHGL) in diﬀerent cell-lines e.g. yeast, insect
and tobacco plant cells.4,51,52 The digestive properties of these
recombinant lipases have not been thoroughly investigated,
but all recombinant lipases showed a lower specific activity
than HGL.4,51,52 A novel rHGL has, however, recently been
expressed in human embryonic kidney cells.53 This has
ensured a similar structure and glycosylation of the protein,
which has resulted in an enzyme with the same specific
activity as HGL.53
Given the recent availability of rHGL, and the incomplete
knowledge on RGL, it would seem critical to compare their
digestive properties to ROL which is used in several estab-
lished models. Thorough investigation of the digestive pro-
perties of these three lipases with regard to the nature and
extent of the FAs released would assist in identifying a suitable
gastric lipase for in vitro gastric digestion with similar digestive
properties as HGL. This is of major importance in the develop-
ment of predictive in vitro digestion models for both the food
and pharmaceutical industry. For this purpose infant formulas
(IF) were chosen as the model substrate given the importance
of HGL in infant digestion.12,13 In addition, there are few
in vitro studies that aim to mimic the biochemical environ-
ment of the infant stomach during digestion. Infants suﬀer
from developmental digestive immaturity which aﬀects proton
pump activity (i.e. gastric pH in the fed state) and bile salt spe-
ciation/reflux.11,54–58 Clinical studies have examined gastric
aspirates from infants fed with diﬀerent IFs providing excel-
lent data on the type and extent of FA released during diges-
tion.10,11 Hence the clinical data on HGL’s catalytic properties
are available in literature and could thus provide the basis for
a comparison with the FA release during in vitro lipolysis of IFs
by diﬀerent commercially available lipases. A key question dis-
cussed in these studies, and paediatric nutrition in general, is
what is the role/extent of MC-FA release during gastric diges-
tion. Therefore, the present study sets out to investigate the
release of FAs during lipolysis of two IF; one containing pre-
dominantly LC-TAGs and one enriched with MC-TAG by three
potential gastric lipase substitutes ROL, RGL and the novel
rHGL. The qualitative release of FAs was compared to pre-
viously published clinical data during gastric digestion of com-
parable IFs.10
Materials and methods
Materials
Sodium taurocholate, sodium chloride, hydrochloric acid,
sodium hydroxide, potassium hydroxide, porcine pepsin,
maleic acid, tris(hydroxymethyl)-aminomethane, porcine pan-
creatin, rhizopus oryzae lipase were purchased from Sigma-
Aldrich (St Louis, MO, USA). Rabbit gastric lipase was kindly
Paper Food & Function
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donated by Germe S.A. (Marseilles, France). The purified rHGL
was donated by Bioneer A/S (Hoersholm, Denmark). The IFs
used were PRENAN Stage 1 & 2 obtained from Nestlé
(Lausanne, Switzerland). PRENAN stage 1 (MC-IF) is enriched
with MC-TAG and PRENAN stage 2 (LC-IF) is a predominantly
LC-TAG formula (Table 1). The lipid composition of the infant
formulas were quantified by gas chromatography (GC) as
explained below in the method section. The methylated FAs
(FAME) standards used for GC were all obtained from Nu-
Chek-Prep (Elysian, MN, USA). All the water used in this study
was of purified Milli Q quality. All other solvents and reagents
were of analytical grade or higher.
In vitro gastrointestinal digestion
The gastrointestinal in vitro lipolysis experiments were carried
out according to Wooster et al. with minor modifications.59
The digestions were conducted in thermostated glass vessels
(37 °C) in either a pH-STAT setup controlled by a TIM 856 bi-
burette pH-STAT (Radiometer Analytical, France) at pH 5.5 or
at a dynamic pH-gradient from 6 to 4 during 60 min by a con-
tinuous addition of HCl at a constant rate via a Harvard
syringe pump (Harvard Apparatus, MA, USA). The gastric
digestions were conducted in 4.25 ml simulated gastric fluid
(Table 2) to which 2 ml of MC-IF or LC-IF were added (only
MC-IF was used as substrate for the dynamic pH experiments).
The digestion was initiated by adding 18 tributyrin units per
ml ((TBU) activity determined at pH 5.4 according to Armand
et al. 1994 7) of either lipase (ROL, RGL or rHGL) and 450
U ml−1 pepsin, based on enzyme levels reported in vivo.2,3,7–9,60
Samples were aspirated after 0, 5, 15, 30, 45 and 60 min and
digestion was stopped by a liquid–liquid extraction of lipids
with chloroform :methanol (2 : 1). The remaining digesta were
diluted 1.7 times with a concentrated intestinal medium to
obtain an environment comparable to the small intestine of a
fed infant (Table 3).55–58 Digestions under intestinal con-
ditions were conducted at pH 6.5 with and without the pres-
ence of pancreatin, to elucidate the digestive capacity of the
gastric lipases under intestinal conditions and to ensure that
the IFs were completely digestible (66% release of FAs).
Samples were taken at 90 min (60 min of gastric digestion +
30 min of intestinal digestion) for the intestinal digestions
without pancreatin and after 180 min (60 min of gastric diges-
tion + 120 min of intestinal digestion) for intestinal digestion
in the presence of pancreatin (300 USP units per ml).
Fatty acid analyses
Fatty acid (FA) analyses were performed on the extracted lipids
at all time points, according to Destaillats et al. 2007.61 The
organic phase (chloroform :methanol 2 : 1) containing the
lipids was transferred to glass test tubes and evaporated to
dryness under nitrogen. The dried lipids were redissolved in
hexane (1 ml) and divided into two fractions of 450 µl, one for
acid methylation and one for alkaline methylation, to deter-
mine all the FAs present in the digesta, including FFA, esters,
alk-1-enyl ethers, amides and glycosides, and to determine the
fraction of FAs bound to glycerol, respectively.62
Acid methylation
Internal standard (100 µl, 0.5 mg ml−1 TAG (C13) + fatty acid
methyl esters (FAME) of C11 in hexane), 2 ml of methanol,
2 ml of methanolic acid (3 N HCl in methanol) and 450 µl
hexane were added to the 450 µl lipid solution. The test tubes
were vortexed vigorously for 1 min before incubation for
60 min at 80 °C and subsequently allowed to cool to room
temperature. After samples had reached room temperature,
2 ml of water was added to seize the methylation and samples
were vortexed for 2 min followed by centrifugation in a
Thermo Scientific Megafuge centrifuge (Osterode, Germany)
(5 min at 1500 rpm 21 °C). The upper phase was collected for GC.
Alkaline methylation
The 450 µl lipid solution was evaporated to dryness under
nitrogen. 100 µl of internal standard (0.5 mg ml−1 TAG(c13) +
Table 1 Composition of major fatty acids in the infant formulas used as
substrates. The values listed are the amounts added to each digestion
and were quantiﬁed by GC
Fatty acids MC-IF (µmol FA) LC-IF (µmol FA)
C8:0 184.8 ± 0.9 11.9 ± 0.1
C10:0 142.5 ± 0.3 9.0 ± 0.0
C12:0 0 56.0 ± 0.1
C14:0 0 23.0 ± 0.0
C16:0 73.1 ± 0.2 109.1 ± 0.1
C18:0 10.1 ± 0.1 15.7 ± 0.0
C18:1 n9 cis 170.2 ± 0.3 242.3 ± 0.0
C18:2 n6 89.1 ± 0.2 92.9 ± 0.1
C18:3 n6 12.2 ± 0.2 11.5 ± 0.1
Total FAs available for digestion 682 571
Table 2 Composition of the medium used for gastric digestions before
dilution with IF
Medium composition Concentration
NaTC 80 µM
NaCl 68 mM
Tris 2 mM
Maleic acid 2 mM
Phospholipid 20 µM
Added to initiate digestion
Pepsin 450 U ml−1
Lipase (ROL, RGL or rHGL) 18 TBU ml−1
Table 3 Final composition of the simulated intestinal ﬂuid after dilution
by gastric digesta
Medium composition Concentration
NaTC 2 mM
NaCl 150 mM
Tris 2 mM
Maleic acid 2 mM
Phospholipid 0.18 mM
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FAME c11 in hexane) and 200 µl 2 M KOH in methanol were
added to the test tube and samples were vortexed for 3.5 min.
The reaction was then seized by the addition of 400 µl 1 M HCL
and samples were briefly vortexed. 900 µl hexane was added
and samples were vortexed for 2 min followed by centrifugation
in a Megafuge centrifuge (Osterode, Germany) (5 min at
1500 rpm 21 °C). The upper phase was collected for GC.
The release of FAs during digestion was measured as the
diﬀerence between all the FAs present (acid methylation) and
FAs bound to glycerol (alkaline methylation).
Gas chromatography
Analyses of the FAMEs were conducted on a 7890 Agilent gas
chromatograph equipped with a flame ionization detector
(Agilent Technologies, Palo Alto, CA, USA). The column was a
fused-silica BPX-70 (10 m × 0.1 mm I.D., 0.2 µm film thick-
ness; SGE, Melbourne, Australia). The settings of the instru-
ment were adopted from Destaillats et al. 2007 and each
sample had a run time of 4.9 min.61
Droplet size
The droplet size of MC- and LC-IFs during dispersion (0 min
digestion) in gastric medium was measured using a
Mastersizer 3000 equipped with a Hydro SM from Malvern
Instruments (Southborough, MA, USA). The laser specifica-
tions of the two lasers are 4 mW 632.8 nm and 10 mW
470 nm. The laser obscuration was approximately 5% and a
refractive index of 1.456 was used. The droplet size of the
LC-IF after 60 min gastric digestion by any of the three lipases
was also investigated.
Droplet morphology
The droplet morphology of LC-IF before and after 60 min
digestion by either ROL, RGL or rHGL was investigated by
scanning electron microscopy (SEM). Sample preparation was
done according to the procedure proposed by Pafumi et al.
2002.63 Emulsions were collected at the desired time point and
mixed at 1 : 1 with 1% Osmium tetroxide solution at room
temperature. The mixture was carefully shaken and few drops
were put on a microscope cover glass. Fixation was performed
overnight in a moist chamber at room temperature. The fixed
emulsion was subsequently gently washed with distilled water
before being dried using a filter paper and a desiccator.
Samples were coated with a 5 nm gold layer before being
observed using a Quanta 200 FEG Scanning Electron
Microscope (FEI Company, The Netherlands) at 10 kV in high
vacuum mode. The droplet morphology of MC-IF could not be
captured by the present sample preparation method, since
Osmium tetroxide only is able to react with double bonds and
saturated FAs are abundant in MC-IF (Table 1).
Results
It was intended to investigate if the experimental setup,
pH-STAT or the more physiological relevant dynamic pH
gradient aﬀected the degree of digestion during lipolysis of
MC-IF by either of the three gastric lipases. However, the
results obtained by the two models were almost superimposa-
ble (Fig. 1). This indicates that the three tested lipases are dis-
playing approximately the same activity in the pH-interval 4 to
6 or that they in average over the course of the experiment
display the same activity in the two setups. Thus digestion of
LC-IF digestion was only carried out by the pH-stat method.
Comparison of fatty acids released during digestion of MC-IF
catalyzed by ROL, RGL and rHGL
FA release catalyzed by ROL, RGL and rHGL during digestion
of MC-IF is shown in Fig. 2a and b. With regard to digestion
by ROL, a lag phase of at least 5 min was seen, where only 4%
of the total FAs available for digestion were liberated (Fig. 2a).
At 15 min of digestion 32% of the FAs were liberated. The rate
of lipolysis then leveled oﬀ and 45% and 46% of the FAs were
liberated after 30 and 60 min, respectively. After 30 min of
intestinal incubation (time point 90 min), without addition of
pancreatin, 61% of the FAs had been hydrolyzed by ROL. It
can furthermore be observed in Fig. 2b that ROL appears
insensitive of FA chain length and abundance, since 50–75%
of all FAs were released relative to their initial composition.
The extent of digestion catalyzed by RGL was modest, com-
pared to ROL; only 0%, 1%, 5%, 10% and 11% of the total FAs
were liberated after 5 min, 15 min, 30 min, 60 min and
90 min, respectively (Fig. 2a). RGL released only C8:0 and
C10:0 under both gastric and intestinal conditions (Fig. 2b),
indicating that RGL is highly specific toward hydrolysis of
medium chain FA. During the digestion catalyzed by rHGL,
4%, 9%, 16% 22% and 23% of the FAs were liberated after
5 min, 15 min, 30 min, 60 min and 90 min, respectively
(Fig. 2a). As for RGL, also rHGL showed a certain specificity
towards hydrolysis of medium chain FA, i.e. C8:0 and C10:0
were released preferentially, but the release of FAs C16:0 to
Fig. 1 Absolute release of total FAs during digestion of MC-IF by ROL,
RGL and rHGL, in the pH-STAT setup and the dynamic pH-gradient
setup. = pH-STAT RGL, = pH-dynamic RGL, = pH-STAT rHGL,
= pH-dynamic rHGL, = pH-STAT ROL, ■ = pH-dynamic ROL.
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C18:2n6 was also evident (Fig. 2b). Furthermore, it is worth
noticing that MC-IF was fully digestible (>66% FA released, as
2-monoglycerides are readily absorbed in vivo) in the presence
of pancreatin (180 min) and either of the tested lipases. Thus
MC-IF seems to be fully digestible under in vitro conditions
simulating the GI-tract of an infant and could therefore also
be believed to be fully digestible in the infant in vivo, securing
optimal nutritional uptake.
Comparison of fatty acids released during digestion of LC-IF
catalyzed by ROL, RGL and rHGL
FA release during digestion of LC-IF by ROL, RGL and rHGL is
shown in Fig. 3a and b. Using ROL as gastric lipase, the initial
digestion occurred very rapidly; 33% of FAs were hydrolyzed
after 5 min. The following digestion rate was slower and 38%,
42% 49% and 66% of the FAs were hydrolyzed after 15 min,
30 min, 60 min and 90 min, respectively (Fig. 3a). As observed
for MC-IF, ROL seems to be insensitive to FA chain length or
abundance, as 50–80% of all FAs were released relative to their
initial composition (Fig. 3b). LC-IF digestion by RGL liberated
6%, 11%, 13%, 18% and 23% after 5 min, 15 min, 30 min,
60 min and 90 min, respectively (Fig. 3a). Again RGL proved to
be sensitive to FA chain length and showed a clear preference
for FAs with shorter chain lengths. The rank order of the
extent of digestion relative to the initial FA composition was
C8:0 > C10:0 > C12:0 > C14:0 > C16:0, with the rest of the FAs
being digested at comparable rates (Fig. 3b). Lauric acid
(C12:0) had the highest total FA release (37 µmol), despite
oleic acid (C18:1) being the most abundant FA in LC-IF. rHGL
hydrolyzed 6%, 12%, 16%, 21% and 24% after 5 min, 15 min,
30 min, 60 min and 90 min of digestion, respectively. The FA
chain length did again appear to matter and the rank order of
the digestion rates with regard to FAs released relative to the
initial composition was C8:0 > C10:0 > C12:0, the rest of the
FAs were liberated at comparable rates (Fig. 3b). Oleic acid
was, however, the most released FA in absolute numbers
(48 µmol) (Fig. 3a).
LC-IF did appear to be fully digestible after addition of pan-
creatic enzymes for ROL and rHGL (>66% FA released). Only
64% of the FAs were released during intestinal digestion in the
presence of pancreatin and RGL, which however, was very
close to full digestibility. Thus LC-IF does also seem to be fully
digestible under experimental conditions simulating the GI-
tract of an infant. This indicates, that all fat in the formula is
available for absorption in vivo.
Droplet morphology
The micrographs of LC-IF before and after gastric digestion by
ROL, RGL and rHGL are shown in Fig. 4a–d. The micrograph
in Fig. 4a shows the oil globules of LC-IF prior to initiation of
digestion. The globules appeared as uniform spherical par-
ticles with a smooth surface/interface. Aggregation seems to be
limited, which is supported by the droplet size data shown in
Table 4, where it can be seen that 90% of the droplets were
smaller than 1.0 µm (Dx (90)) and 50% were smaller than
0.5 µm (Dx (50)). The morphological change of the oil globules
Fig. 2 (a) Absolute release of FAs during digestion of MC-IF by ROL, RGL and rHGL. The percentages indicate the percentage of FAs liberated rela-
tive to the total amount present in MC-IF. (b) Release of FA relative to the initial composition in the IF during digestion of MC-IF catalyzed by ROL,
RGL and rHGL. The dotted lines indicate change from gastric to intestinal conditions. The dashed lines indicates digestion in the presence of pan-
creatin. = C8:0, = C10:0, = C16:0, = C18:0, = C18:1n9 cis, ■ = C18:2n6, = C18:3n6.
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after 60 min of digestion by ROL can be seen in Fig. 4b. It is
evident that the integrity of the globules has been disrupted
and their spherical shape was almost completely lost. The
surface was no longer smooth. Furthermore, there were indi-
cations of extensive aggregation, which again was supported
by the droplet size data in Table 4, where an almost 10-fold
increase in Dx (50) to 4.2 µm was observed. A representative
example of the appearance of the oil globules after 60 min
digestion by RGL can be seen in Fig. 4c. The spherical shape
of the globules was intact, however small spherical protrusions
were present on the surface of the droplets. The droplet size
measurements showed an increase in Dx (50) and Dx (90) to
Fig. 3 (a) Absolute release of FAs during digestion of LC-IF by ROL, RGL and rHGL. The percentages indicate the amount of FAs liberated relative to
the total amount present in LC-IF. (b) Release of FA relative to the initial composition in the IF during digestion of LC-IF catalyzed by ROL, RGL and
rHGL. The dotted lines indicate change from gastric to intestinal conditions. The dashed lines indicate intestinal digestion in the presence of pan-
creatin. = C8:0, = C10:0, = C12:0, = C14:0, = C16:0, = C18:0, = C18:1n9 cis, ■ = C18:2n6, = C18:3n6.
Fig. 4 SEM micrographs of a: LC-IF prior to digestion, b: LC-IF after 60 min gastric digestion by ROL, c: LC-IF following 60 min gastric digestion by
RGL, and d: LC-IF following 60 min gastric digestion by rHGL.
Table 4 Droplet size data of MC-IF and LC-IF prior to digestion and after 60 min gastric digestion of LC-IF by ROL, RGL and rHGL, determined by
laser diﬀraction
Sample name Digestion time (min) D [3,2] (µm) D [4,3] (µm) Dx (10) (µm) Dx (50) (µm) Dx (90) (µm)
MC-IF 0 0.3 ± 0.0 0.5 ± 0.0 0.2 ± 0.0 0.4 ± 0.0 0.8 ± 0.0
LC-IF 0 0.4 ± 0.0 0.6 ± 0.0 0.2 ± 0.0 0.5 ± 0.0 1.0 ± 0.1
LC-IF ROL 60 4.0 ± 0.8 4.6 ± 1.0 2.7 ± 0.5 4.2 ± 0.9 7.0 ± 1.7
LC-IF RGL 60 0.4 ± 0.0 4.1 ± 0.8 0.2 ± 0.0 0.5 ± 0.0 12.7 ± 1.2
LC-IF rHGL 60 0.2 ± 0.0 1.0 ± 0.0 0.1 ± 0.0 0.4 ± 0.0 2.7 ± 0.0
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0.5 µm and 12.7 µm, respectively, following RGL digestion.
The same trend was found after 60 min of digestion by rHGL,
where globule integrity appeared uncompromised and there
were many small spherical protrusions present at the surface
of the droplets. The droplet size was altered modestly to
0.4 µm and 2.7 µm for Dx (50) and Dx (90), respectively.
Discussion
Comparison of in vitro digestion of MC-IF by ROL, RGL
and rHGL
Great diﬀerences were observed between the digestive pro-
perties of the three lipases tested (Fig. 2a and b). The diﬀer-
ences were not only evident in the total extent of digestion, but
also in the preference for hydrolysis of FAs of diﬀerent chain
length. The extent of digestion catalyzed by ROL (46% after
60 min gastric digestion) was considerably higher than for the
other two lipases (10% and 22% for RGL and rHGL, respect-
ively). This is remarkable since the same standardized amount
of lipase activity (18 TBU ml−1) was present during the experi-
ment for all three lipases. This shows that ROL has diﬀerent
digestive properties compared to the other two lipases. The
extent of digestion by ROL was also significantly higher than
what has been reported for HGL in vivo, where 10–45% of the
total hydrolysis occurred via gastric digestion.1 Total hydrolysis
of a TAG corresponds to 66% liberation of the FAs present,
hence 46% FAs released by ROL corresponds to 69% of the
total hydrolysis.43,44 Furthermore, ROL catalyzed extensive
digestion under intestinal conditions where hydrolysis
increased from 46 to 61% of all FAs present (92% of the total
hydrolysis). In addition it was apparent that ROL digested FAs
of all chain lengths at approximately the same rate relative to
their initial composition in the IF. This is in contrast with
in vivo data for HGL by Hamosh et al. on the digestion of IFs
with a similar lipid composition.10 In their study, gastric
samples were aspirated 15 min after feeding of IFs to
infants.10 It was shown that MC-FAs were clearly the preferred
substrate for HGL catalyzed hydrolysis when MC-TAG was
present in combination with LC-TAGs, even though small
amounts of LC-FAs were also released. In another study by
Roman et al. samples were aspirated from the stomach after
dosing of an MC-TAG enriched IF to infants.11 The authors did
not see a clear preference for MC-TAGs as a substrate for
HGL.11 However, they did not sample until 90 min after dosing
and were therefore not able to see an initial preference for
MC-TAG.
Thus ROL’s lack of specificity with regard to fatty acid chain
length does not replicate the action of HGL in vivo. This is
indeed a problem if one wants to utilize gastrointestinal diges-
tion models to evaluate if newly developed nutritional pro-
ducts or drug delivery systems are substrates for gastric
digestion. ROL would then misleadingly show that all FAs are
released at more or less the same rate. The non-specific diges-
tive pattern of ROL could potentially also be a problem for the
assessment of micronutrient or API solubilization by colloidal
structures, as the solubilizing capacity of digestion products
following hydrolysis of MC-TAGs and LC-TAGs is diﬀerent.49,50
Thus based on the current study, ROL does not seem to repli-
cate the digestive properties of HGL and is therefore not an
appropriate surrogate for HGL in gastric in vitro lipolysis
models.
RGL and rHGL both showed a higher aﬃnity for the
MC-FAs during digestion of MC-IF, which is a similar prefer-
ence to what has been previously reported in vivo.10 RGL did,
however, only release MC-FAs, whereas rHGL predominantly
released MC-FAs but also LC-FAs to some degree. Only very
modest digestion occurred under intestinal conditions for
both lipases (approximately 1%). This is another important
diﬀerence between ROL and the other two lipases. However, it
is diﬃcult to determine what would occur in vivo, due to the
inherent presence of pancreatic lipases. The in vitro gastric
digestion by rHGL seemed to replicate the digestive properties
of HGL in vivo both with regards to total extent of digestion,
but also fatty acid chain length preference.10 RGL also seems
to be an acceptable candidate as a surrogate for HGL, since
the extent of digestion is within the range reported in vivo and
has a similar preference for MC-FA. It would, however, (mis-
leadingly) show that LC-TAGs are not a substrate if present in
the same blend as MC-TAGs and should therefore be used
with care. An explanation for RGL’s selective preference for
MC-TAGs could possibly be found in the fact that rabbit’s milk
is rich in MC-TAGs (approximately 75% C8 and C10).64 It does
therefore seem plausible from an evolutionary point of view
that MC-TAGs are excellent substrates for RGL. Thus a com-
parison between the current study and previously reported
in vivo data by Hamosh et al.,10 revealed that a rank order
could be constructed indicating which lipase replicated the
digestive pattern of HGL the best: rHGL > RGL > ROL.
Comparison of in vitro digestion of LC-IF by ROL, RGL
and rHGL
The results in Fig. 3a and b showed substantial diﬀerences
between the digestive properties of the three gastric lipases.
ROL again showed a higher extent of gastric hydrolysis (49%
release of the total FAs present in the IF after 60 min digestion)
compared to the two other lipases which hydrolysed 23% and
24% for RGL and rHGL, respectively. The chain length speci-
ficity/preference also varied between the three diﬀerent
lipases. ROL again seemed to hydrolyze FAs more or less indis-
criminate of chain length compared to the other two lipases,
which displayed clear preferences towards MC FAs. The insen-
sitivity of ROL to FA chain length is not in line with what had
previously been reported for HGL during the in vivo digestion
of a LC-IF, where C8:0 and C10:0 were the first site of hydro-
lysis followed by C18:1.10 In our current study, RGL showed a
clear preference towards MC-TAGs, C12:0 was the most
released FA in absolute numbers and not C18:1. In vivo diges-
tion of two commercial infant formulas with similar FA com-
positions suggest that whilst considerable amounts of MC-FAs
are released by HGL action in the stomach, long chain FAs,
specifically C18:1 and C18:2, are the largest fraction of FA in
Food & Function Paper
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the stomach contents.10 The balance between amount of C12
and C18:1 FA released observed in vivo by Hamosh et al. were,
however, replicated during the digestion of LC-IF catalyzed by
rHGL, since rHGL showed a preference towards MC-TAGs, but
C18:1 was the most released FA.10 Thus if one should construct
the rank order at which the three diﬀerent gastric lipases repli-
cated the digestive properties of HGL it would again be rHGL >
RGL > ROL as observed during the digestion of MC-IF.
The diﬀerences in the digestive pattern of the three tested
lipases do not only aﬀect the total extent of digestion and the
relative preference for diﬀerent FA chain length, but also the
morphology of the resulting oil globules, as observed from the
SEM micrographs in Fig. 4a–d and the droplet size measure-
ments in Table 4. The extensive gastric digestion occurring
during ROL hydrolysis had completely disrupted the spherical
shape of the oil globules, and droplet aggregation seemed
evident. This was also confirmed by the droplet size data were
Dx (50) Dx (90) were 4.2 µm and 7.0 µm, respectively, which was
considerably higher than the droplet size prior to digestion. The
oil globules after gastric digestion by RGL and rHGL were very
similar in appearance and the spherical shape was still intact.
However, unusual spherical protrusions were observed on the
surface of the lipid droplets after gastric digestion by both RGL
and rHGL. Such protrusions have only been reported in a few
studies. They were initially discovered by Pafumi et al. during
in vitro digestion of model emulsions and Gallier et al. recently
observed similar structures during the in vivo digestion of
bovine milk.63,65 Pafumi et al. explored the role these structures
played in the inhibition of gastric lipolysis and reported that
these structures are largely composed of free FAs (73.7% long
chain), phospholipids (15.6%) and MAGS and DAGS (8.5%),
resulting from the digestive action of HGL.63 Pafumi et al.
propose that the build-up of poorly water-soluble LC-FA at the
interface inhibit the action of HGL by forming the lipidic pro-
trusions which envelop HGL preventing it from accessing TAGs
at the interface.63 The fact that RGL and rHGL replicate this be-
havior highlights the similarity in their surface behavior to
HGL. The presence of extensive gastric hydrolysis in vitro by
ROL suggests it has very diﬀerent surface properties to HGL as
it is not inhibited by the build-up of LC-FA digestion products.
Diﬀerences between RGL and rHGL were, however, indi-
cated in the droplet size measurements in Table 4. The Dx (50)
and Dx (90) were 0.54 µm and 12.74 µm following RGL diges-
tion and 0.39 µm and 2.7 µm following rHGL digestion,
respectively. This suggests that more extensive aggregation of
the oil droplets occurred following digestion by RGL compared
to rHGL. Thus, even though the extent of digestion was very
similar between RGL and rHGL, the resulting digestion pro-
ducts had diﬀerent propensities for droplet aggregation. This
indicates that the choice of lipase does not only aﬀect sub-
strate specificity or regio- or stereo-specifity, but also the result-
ing droplet morphology. This could potentially be important
for micronutrient and API absorption since the colloidal struc-
tures would diﬀer depending on the lipase used. The rate of
intestinal digestion might also be altered with the change of
surface area available for hydrolysis. This was actually observed
in the present study, the extent of intestinal digestion by pan-
creatin was 64% and 72% in the presence of RGL and rHGL,
respectively. Thus aggregation of oil droplets following gastric
digestion by RGL could explain the reduced extent of intestinal
digestion compared to rHGL. It should, however, be noted that
other factors than the surface area available for digestion,
could influence the extent of intestinal digestion, such as the
FA composition on the remaining TAGs and DAGS.
Overall when MC-IF and LC-IF were digested in the two
compartment digestion model (containing gastric lipase and
pancreatin) both formulas underwent complete digestion.
Under human in vivo conditions complete digestion occurs at
approximately 66.6% hydrolysis, i.e. the conversion of the TAG
into a MAG and two FAs.66 Digestion of the two formulas in
the presence of RGL/(porcine)pancreatin resulted in 67%
(MCT) and 64% hydrolysis (LCT) whilst for rHGL/pancreatin
resulted in 77 and 72% hydrolysis respectively. Interestingly,
digestion by ROL/pancreatin resulted in 83 and 94% hydrolysis
of MC-IF and LC-IF, respectively, well above what would nor-
mally be expected in vivo. The higher than expected hydrolysis
for ROL/pancreatin was quite surprising, but could possibly be
attributed to acyl migration and/or reactivity at the sn-2 posi-
tion at elevated pH-levels or in cooperation with other lipases,
such as carboxylester hydrolase present in porcine pancreatin.67,68
Conclusion
The digestions of MC-IF and LC-IF by ROL, RGL and rHGL
revealed that the lipases varied both with regard to the extent
of digestion, FA aﬃnity and morphology changes of oil glo-
bules during digestion. ROL showed a much higher extent of
digestion than expected based on previous in vivo data both
under gastric and intestinal conditions and was furthermore
indiscriminative of FA chain length and abundance. RGL and
rHGL both showed an extent of digestion within the expected
range and they furthermore displayed a preference towards
MC-TAGs. RGL did, however, only release MC-FAs during the
digestion of MC-IF whereas rHGL predominantly hydrolyzed
MC-TAGs, but also some LC-TAGs. Previously reported in vivo
data states that MC-TAGs are preferentially hydrolyzed in vivo
but also some digestion of LC-TAGs occur. A result replicated
by rHGL, but not RGL. The digestion of LC-IF also revealed
that rHGL seemed to replicate the digestive pattern observed
in vivo with regard to FA specificity. Furthermore the formation
of lumbs on the oil droplet surface during digestion catalyzed
by HGL, as observed previously by Pafumi et al. and Gallier
et al., was reproduced by RGL and rHGL in this present
study.63,65 Hence RGL and rHGL seem to have similar surface
properties as HGL. Thus, of the tested lipases, rHGL seems to
be the best surrogate for HGL for in vitro digestion models.
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